Milrinone (Lactate)

Also known as: Milrinona

Drug #1565

Milrinone (Lactate) is a phosphodiesterase III inhibitor similar to amrinone, with +ve ionotropic and vasodilator activity. It potentiate effects of cyclic adenosine monophosphate(cAMP). Milrinone (Lactate) is administered intravenosly in the management of heart failure(severe) unresponsive to other form & in acute heart failure after cardiac surgery.

← Previous drug Next drug →

Primary Characteristics

Milrinone (Lactate) is also known as Milrinona.

It is of Synthetic origin and belongs to Bipyridine.

Molecular Weight: 301.3 · pK_a: 4.5, 8.5, 8.6 · Solubility in Water: < 1 in 10000 · Solubility in Alcohol: > 1 in 1000 · Non-proprietary name: Milrinone (Lactate) · pH: 3.2.

Molecular structure of Milrinone (Lactate)

Pharmacokinetics

Absorption: Milrinone (Lactate) has an oral bioavailability is 82.5% (±2.5%).

Distribution: Milrinone (Lactate) has a volume of distribution is 0.32 l/kg. plasma protein binding is 70 %.

Elimination: it is metabolised via hepatic(12%), plasma half-life is 2-3 hr, renal excretion is 83 % unchanged.

Indications

Milrinone (Lactate) is primarily indicated in conditions like Acute heart failure, Congestive heart failure, Heart failure, Short-term treatment of severe congestive heart failure, Tobacco amblyopia and leber's optic atrophy.

Contraindications

Milrinone (Lactate) is contraindicated in conditions like Allergy, Hypotension, Ventricular arrhythmias, Hypersensitivity, Pregnancy, Supraventricular arrhythmias, Prophylaxis of mycobacterium avium complex infections.

Dosage

Milrinone (Lactate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
50 mcg/kg	50 mcg/kg	—	IV	Initial loading dose loading over 10
562.5 nanogram/min	562.5 nanogram/min	—	IV	Maintanace,continouse I.V, Total dose should not exceed 1.13 mg/kg.
Paediatric Dosage (20kg)
50 – 75 mcg/kg	—	—	IV	Initial dose over dose over 30-60 min
30 – 45 mcg/kg	—	Every 1h	IV	Continous IV usually for 12hr after cardiac surgery (reduce or omit loading dose it risk of hypotens
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown4 interactions

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Milrinone (Lactate) in overdosage may give rise to further complications which include Hypotension , Bronchospasm , Hypotension , Bronchospasm , Angina , Anaphylaxis , Supraventricular arrhythmia, Ventricular arrhythmia.

Milrinone (Lactate) produces potentially life-threatening effects which include Arrhythmias, Hypotension. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Milrinone (Lactate) are Hypotension.

Milrinone (Lactate) is known to cause more or less tolerable side effects which are usually transient. These include Angina, Headache, Hypokalemia , Hypotension , Nausea, Palpitation, Rashes , Somnolence , Thrombocytopenia, Tremor.

Warnings / Precautions

Blood pressure, heart rate, ECG, fluid and electrolyte balance should be monitored during therapy. It should be used with caution in patients with severe obstructive aortic or pulmonary valvular disease or with hypertrophic cardiomyopathy and in children and in patients with decreased renal function,hypokalemia,hypotension.

Interference in Pathology

Milrinone (Lactate) may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

10 mg

Storage Conditions

Milrinone (Lactate) should be stored IV Inj, IV Inf.

Drug Classification

1.12.4 — Drugs used in heart failure

Manufacturers

Manufacturers of Milrinone (Lactate) in Pakistan:

Atco